Abstracts tagged "interdisplinary and pediatric rheumatology"

Abstract Number: 3093 • 2015 ACR/ARHP Annual Meeting
Development and Validation of Diagnostic Criteria for Cryopyrin Associated Periodic Syndromes
Jasmin B. Kuemmerle-Deschner¹, Seza Ozen², Pascal N. Tyrrell³, Isabelle Koné-Paut⁴, Raphaela Goldbach-Mansky⁵, Helen Lachmann⁶, Norbert Blank⁷, Hal M. Hoffman⁸, Elisabeth Weissbarth-Riedel⁹, Boris Huegle¹⁰, Tilmann Kallinich¹¹, Marco Gattorno¹², Ahmet Gul¹³, Nienke M. ter Haar¹⁴, Marlen Oswald¹⁵, Fatma Dedeoglu¹⁶ and Susanne M. Benseler¹⁷, ¹Universitätsklinikum Tübingen, Klinik fuer Kinder- und Jugendmedizin, Tübingen, Germany, ²Pediatric Nephrology and Rheumatology, Hacettepe University, Ankara, Turkey, Ankara, Turkey, ³Department of Medical Imaging, University of Toronto, Toronto, ON, Canada, ⁴Pediatrics Rheumatology, CHU Bicêtre, Le Kremlin Bicêtre, France, ⁵Bldg10 rooom 6D47-B, NIH | NIAMS, Bethesda, MD, ⁶UK National Amyloidosis Centre, University College London Medical School, London, United Kingdom, ⁷Med 5-Rheumatology, University of Heidelberg, Heidelberg, Germany, ⁸University of California at San Diego, San Diego, CA, ⁹Rheumatology, Pediatrics, Universitaetskinderklinik Hamburg, Hamburg, Germany, ¹⁰Pediatric Rheumatology, German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, ¹¹Charite, University Medicine Berlin, Berlin, Germany, ¹²Pediatry, G. Gaslini Institute, Genova, Italy, ¹³Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ¹⁴Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ¹⁵University Hospital Tuebingen, Tuebingen, Germany, ¹⁶Division of Immunology, Boston Children's Hospital, Boston, MA, ¹⁷Rheumatology, Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada
Background/Purpose: Cryopyrin Associated Periodic Syndromes (CAPS) are a rare, clinically heterogeneous group of devastating inflammatory illnesses. NLRP3gene gain-of function mutations result in unceasingly raised IL1…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].